CPHI Online is the largest global marketplace in the pharma ingredients industry

  • Products
    0
  • Companies
    0
  • Articles
    0
  • Events
    0
  • Webinars
    0
Read more about CPHI
24
Jun
2025

Techpool Bio-Pharma Co., Ltd.

Exhibitor at CPHI & PMEC China 2025 stand E9A19, Finished Dosage
About Us

Techpool focuses on the critical care injection R&D, production, marketing, and sells. 

The main products: 1. Ulinastatin for injection (UTI), Sales volum - about 11 million vials/year, Indications - Acute pancreatitis & Sepsis, and Techpool UTI used to treat severe patients with COVID-19 in China and Pakistan.
2. Urinary Kallidinogenase for injection (KLK), it is original, its indication is Mild-moderate ischemic stroke.

Techpool is one of Shanghai Pharma (Forturne 500) members, it was founded in 1993 in China, with a site area of 50,000 m². 

Read more Show less
Sales Markets
Show more Show less
Categories
more categories Show less
  • CN
  • 2015
    On CPHI since
  • 1000 - 4999
    Employees
Company types
Manufacturer/Innovator
View company profile
Contact info
Show contact info Hide contact info
Event information
CPHI & PMEC China 2025
  • 24 Jun 2025 - 26 Jun 2025
  • Shanghai New International Expo Center
  • Visit us at stand E9A19, Finished Dosage

Products Featured at CPHI & PMEC China 2025

  • Ulinastatin for Injection (UTI)

    Product Ulinastatin for Injection (UTI)

    UTI is a standard therapy for physicians and surgeons to treat the patients with Acute Pancreatitis, which can Protect the organ function and Reduce the incidence of complication and mortality.

    UTI is a unique treatment choice for physicians to treat the patients with ACF and Sepsis, in E...
  • Urinary Kallidinogenase for Injection (KLK)

    Product Urinary Kallidinogenase for Injection (KLK)

    Urinary Kallidinogenase for injection (KLK) is listed in Medical Insurance and Reimbursement List in China.

    KLK is the first choice to treat patients with Mild – Moderate Acute Thrombotic Cerebral Infarction, especially, for the patients who miss the treatment window of thrombolytic therapy, whic...